对话田文志：被“误读”的吉利德临床失利，与CD47靶点的应许之地
吉利德“翻车”，不仅引发业界对吉利德药物开发方案的质疑，各类解读更多指向了CD47靶点的成药性问题。
Time：
2023-08-09 09:16
Author：
xieyijun
爱思唯尔发布全新Scopus AI专业测试版丨生成式AI技术结合海量可信赖信息，推动科研效率快速提升
Time：
2023-08-02 09:18
Author：
xieyijun
股价跌幅创三年来新低，烧钱只维持到2027年的Vir能东山再起吗?
Time：
2023-07-31 09:16
Author：
xieyijun
Recommended content
WCLC 2026 | Hansun "Blows the Roof Off", the New King of B7-H3 ADC is About to be Crowned
It's time for Chinese innovative drugs to redefine the standards.
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务